6. Limitations
Silicon does not form double bond containing compound like common carbon (C=C, C=O) system. However, it cannot form physiologically stable Si-H, because the bond itself is weaker than the C-H bond and has reverse polarity [Si(¥ä+)-H(¥ä−) versus C(¥ä−)-H(¥ä+)]. Hence, Si-H bond behaves differently than C-H and easily cleaved by water under non acidic
condition forming corresponding silanol (Si-OH).
7. Conclusion
This short review highlighted the current prospect of silicon in drug discovery process. Flexible properties of organosilicons such as hydrogen bonding capability, hydrophobicity, acidity and no associated toxicity made its impact in inhibitor design and synthesis for the number of drug targets (antimicrobial, anticancer and antiviral). Poorly permeable
drug can be modified for the increase in cell penetration by incorporating silicon isostere. Moreover, release of drug can be controlled using silicon prodrug. The diverse properties of silicon will be used in near future to solve the number of problems associated in drug discovery. Though, the organosilicons are making its impact in drug discovery process, but it has long way to go.
References
[1] A. K. Franz and S. O. Wilson, ¡°Organosilicon Molecules with Medicinal Applications¡±, J. Med. Chem., DOI: 10.1021/jm3010114, 2012.
[2] M. J. Barnes, R. Conroy, D. J. Miller, J. S. Mills, J. G. Montana, P. K. Pooni, G. A. Showell, L. M. Walsh, and J. B. H. Warneck, ¡°Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: A new use of silicon bioisosteres in medicinal chemistry¡±, Bioorg. Med. Chem. Lett., Vol. 17, pp. 354-357, 2007.
[3] S. McN. Sieburth, T. Nittoli, A. M. Mutahi, and L. Guo, ¡°Silanediols: A new class of potent protease inhibitors¡±, Angew. Chem. Int. Ed., Vol.37, pp. 812-814, 1998.
[4] R. Tacke, V. I. Handmann, R. Bertermann, C. Burschka, M. Penka, and C. Seyfried, ¡°Silaanalogues of high-affinity, selective ¥ò ligands of the spiro[indane-1,4'-piperidine] type: Syntheses, structures, and pharmacological properties¡±, Organometallics, Vol. 22, pp. 916-924, 2003.
[5] R. Tacke, T. Heinrich, R. Bertermann, C. Burschka, A. Hamacher, and M. U. Kassack, ¡°Sila-haloperidol: A silicon analogue of the dopamine (D2) receptor antagonist haloperidol¡±, Organometallics, Vol.23, pp. 4468-4477, 2004.
[6] S. J. Cho, ¡°Calculation and application of partial charges¡±, J. Chosun Natural Sci., Vol. 3, pp. 226-230, 2010.
[7] S. J. Cho, ¡°Meaning and definition of partial charges¡±, J. Chosun Natural Sci., Vol. 3, pp. 231-236, 2010.
[8] G. Kothandan, T. Madhavan , C. G. Gadhe, and S. J. Cho, ¡°Pseudoreceptor: concept and overview¡±, J. Chosun Natural Sci., Vol. 3, pp. 162-167, 2010.
[9] C. G. Gadhe and S. J. Cho, ¡°Modulation of multidrug resistance in cancer by p-glycoprotein¡±, J. Chosun Natural Sci., Vol. 4, pp. 23-30, 2011.
[10] S. J. Cho, ¡°Search space reduction techniques in small molecular docking¡±, J. Chosun Natural Sci., Vol. 3, pp. 143-147, 2010.
[11] H. W. Chung and S. J. Cho, ¡°Recent development of scoring functions on small molecular docking ¡±, J. Chosun Natural Sci., Vol. 3, pp. 49-53, 2010.
[12] G. A. Showell and J. S. Mills, ¡°Chemistry challenges in lead optimization: Silicon isosteres in drug discovery¡±, Drug Discov. Today, Vol.8, pp. 551-556, 2003.
[13] P. K. Pooni and G. A. Showell, ¡°Silicon switches of marketed drugs¡±, Mini-Rev. Med. Chem., Vol. 6, pp. 1169-1177, 2006.
[14] A. K. Franz, ¡°The synthesis of biologically active organosilicon small molecules¡±, Curr. Opin. Drug Discovery Dev., Vol. 10, pp. 654-671, 2007.
[15] S. McN. Sieburth and C.-A. Chen, ¡°Silanediol protease inhibitors: From conception to validation¡±, Eur. J. Org. Chem., Vol. 2006, pp. 311-322, 2006.
[16] S. Gately and R. West, ¡°Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds¡±, Drug Dev. Res., Vol. 68, pp. 156-163, 2007.
[17] W. Bains and R. Tacke, ¡°Silicon chemistry as a novel source of chemical diversity in drug design¡±, Curr. Opin. Drug Discovery Dev., Vol. 6, pp. 526-543, 2003.
[18] F. D. Osterholtz and E. R. Pohl, ¡°Kinetics of the hydrolysis and condensation of organofunctional alkoxysilanes: A review¡±, J. Adhes. Sci. Technol., Vol.6, pp. 127-149, 1992.
[19] J. S. Mills and G. A. Showell, ¡°Exploitation of silicon medicinal chemistry in drug discovery¡±, Expert Opin. Invest. Drugs,Vol.13, pp. 1149-1157, 2004.
[20] F. T. Chiu, Y. H. Chang, G. Ozkan, G. Zon, K. C. Fichter, and L. R. Phillips, ¡°Synthesis, hydrolytic reactivity, and anticancer evaluation of N- and O-triorganosilylated compounds as new types of potential prodrugs¡±, J. Pharm. Sci., Vol.71, pp. 542-551, 1982.
[21] T. Johansson, L. Weidolf, F. Popp, R. Tacke, and U. Jurva, ¡°In vitro metabolism of haloperidol and sila-haloperidol: New metabolic pathways resulting from carbon/silicon exchange¡±, Drug Metab. Dispos., Vol.38, pp. 73-83, 2010.
[22] M. C. Parrott, M. Finniss, J. C. Luft, A. Pandya, A. Gullapalli, M. E. Napier, and J. M. DeSimone, ¡°Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles¡±, J. Am. Chem. Soc., Vol.134, pp. 7978-7982, 2012.
[23] J. O. Daiss, C. Burschka, J. S. Mills, J. G. Montana, G. A. Showell, I. Fleming, C. Gaudon, D. Ivanova, H. Gronemeyer, and R. Tacke, ¡°Synthesis, crystal structure analysis, and pharmacological characterization of disila-bexarotene, a disila-analogue of the RXR-selective retinoid agonist bexarotene¡±, Organometallics, Vol.24, pp. 3192-3199, 2005.
[24] J. O. Daiss, C. Burschka, J. S. Mills, J. G. Montana, G. A. Showell, J. B. H. Warneck, and R. Tacke, ¡°Sila-venlafaxine, a sila-analogue of the serotonin/noradrenaline reuptake inhibitor venlafaxine: Synthesis, crystal structure analysis, and pharmacological characterization¡±, Organometallics, Vol. 25, pp. 1188-1198,2006.
[25] M. Chang, S.-R. Park, J. Kim, M. Jang, J. H. Park, J. E. Park, H.-G. Park, Y.-G. Suh, Y. S. Jeong, Y.-H. Park, and H.-D. Kim, ¡°Silicon switch approach in TRPV1 antagonist MK-056and its analogues¡±, Bioorg. Med. Chem., Vol.18, pp. 111-116, 2010.
[26] J. O. Daiss, C. Burschka, J. S. Mills, J. G. Montana, G. A. Showell, J. B. H. Warneck, and R. Tacke, ¡°Sila-venlafaxine, a sila-analogue of the serotonin/noradrenaline reuptake inhibitor venlafaxine: Synthesis, crystal structure analysis, and pharmacological characterization¡±, Organometallics, Vol. 25, pp. 1188-1198, 2006.
[27] M. Blunder, N. Hurkes, S. Spirk, M. List, and Pietschnig, R. ¡°Silanetriols as in vitro inhibitors for AChE¡±, Bioorg. Med. Chem. Lett., Vol. 21, pp. 363-365, 2011.
[28] Y.-M. Kim, S. Farrah, and R. H. Baney, ¡°Structure-antimicrobial activity relationship for silanols, a new class of disinfectants, compared with alcohols and phenols¡±, Int. J. Antimicrob. Agents, Vol.29, pp. 217-222,2007.
|